nodes	percent_of_prediction	percent_of_DWPC	metapath
Imipramine—HRH1—atherosclerosis	0.383	1	CbGaD
Imipramine—CYP3A7-CYP3A51P—Simvastatin—atherosclerosis	0.0306	0.0822	CbGbCtD
Imipramine—CYP3A7—Simvastatin—atherosclerosis	0.0306	0.0822	CbGbCtD
Imipramine—CYP3A7—Lovastatin—atherosclerosis	0.0299	0.0805	CbGbCtD
Imipramine—CYP3A7-CYP3A51P—Lovastatin—atherosclerosis	0.0299	0.0805	CbGbCtD
Imipramine—CYP2B6—Simvastatin—atherosclerosis	0.0291	0.0783	CbGbCtD
Imipramine—CYP2C19—Rosuvastatin—atherosclerosis	0.0199	0.0535	CbGbCtD
Imipramine—CYP2C19—Simvastatin—atherosclerosis	0.0185	0.0497	CbGbCtD
Imipramine—CYP2C19—Lovastatin—atherosclerosis	0.0181	0.0487	CbGbCtD
Imipramine—CYP2D6—Niacin—atherosclerosis	0.0178	0.0478	CbGbCtD
Imipramine—ABCB1—Ezetimibe—atherosclerosis	0.0161	0.0432	CbGbCtD
Imipramine—ABCB1—Simvastatin—atherosclerosis	0.0149	0.0401	CbGbCtD
Imipramine—ABCB1—Lovastatin—atherosclerosis	0.0146	0.0393	CbGbCtD
Imipramine—ABCB1—Pravastatin—atherosclerosis	0.0146	0.0393	CbGbCtD
Imipramine—CYP2D6—Simvastatin—atherosclerosis	0.0141	0.0378	CbGbCtD
Imipramine—CYP2D6—Pravastatin—atherosclerosis	0.0138	0.037	CbGbCtD
Imipramine—CYP2D6—Lovastatin—atherosclerosis	0.0138	0.037	CbGbCtD
Imipramine—CYP3A4—Rosuvastatin—atherosclerosis	0.00963	0.0259	CbGbCtD
Imipramine—CYP3A4—Ezetimibe—atherosclerosis	0.00963	0.0259	CbGbCtD
Imipramine—CYP3A4—Simvastatin—atherosclerosis	0.00895	0.024	CbGbCtD
Imipramine—CYP3A4—Lovastatin—atherosclerosis	0.00876	0.0235	CbGbCtD
Imipramine—CYP3A4—Pravastatin—atherosclerosis	0.00876	0.0235	CbGbCtD
Imipramine—HTR2A—arteriole—atherosclerosis	0.00216	0.0932	CbGeAlD
Imipramine—HTR7—vein—atherosclerosis	0.00206	0.0891	CbGeAlD
Imipramine—HTR2A—vein—atherosclerosis	0.00129	0.0555	CbGeAlD
Imipramine—HTR2A—hindlimb—atherosclerosis	0.000856	0.0369	CbGeAlD
Imipramine—KCND2—cardiovascular system—atherosclerosis	0.000846	0.0365	CbGeAlD
Imipramine—HTR7—artery—atherosclerosis	0.000841	0.0363	CbGeAlD
Imipramine—KCND2—adipose tissue—atherosclerosis	0.000746	0.0322	CbGeAlD
Imipramine—KCND3—cardiovascular system—atherosclerosis	0.000738	0.0318	CbGeAlD
Imipramine—HTR2A—appendage—atherosclerosis	0.000734	0.0317	CbGeAlD
Imipramine—HTR7—endothelium—atherosclerosis	0.00071	0.0306	CbGeAlD
Imipramine—HTR7—blood vessel—atherosclerosis	0.000655	0.0283	CbGeAlD
Imipramine—KCND3—adipose tissue—atherosclerosis	0.00065	0.0281	CbGeAlD
Imipramine—Infestation—Ezetimibe—atherosclerosis	0.000526	0.0045	CcSEcCtD
Imipramine—Neuropathy peripheral—Lovastatin—atherosclerosis	0.000525	0.00449	CcSEcCtD
Imipramine—HTR2A—artery—atherosclerosis	0.000524	0.0226	CbGeAlD
Imipramine—Erectile dysfunction—Simvastatin—atherosclerosis	0.000518	0.00443	CcSEcCtD
Imipramine—Neuropathy peripheral—Ezetimibe—atherosclerosis	0.000515	0.00441	CcSEcCtD
Imipramine—Photosensitivity reaction—Simvastatin—atherosclerosis	0.000513	0.00439	CcSEcCtD
Imipramine—Jaundice—Ezetimibe—atherosclerosis	0.000512	0.00438	CcSEcCtD
Imipramine—Arrhythmia—Rosuvastatin—atherosclerosis	0.000507	0.00434	CcSEcCtD
Imipramine—Eosinophilia—Pravastatin—atherosclerosis	0.000503	0.0043	CcSEcCtD
Imipramine—Mental disorder—Rosuvastatin—atherosclerosis	0.000497	0.00425	CcSEcCtD
Imipramine—Hepatobiliary disease—Ezetimibe—atherosclerosis	0.000497	0.00425	CcSEcCtD
Imipramine—Neuropathy peripheral—Simvastatin—atherosclerosis	0.000491	0.0042	CcSEcCtD
Imipramine—Jaundice—Simvastatin—atherosclerosis	0.000489	0.00418	CcSEcCtD
Imipramine—Hepatitis—Lovastatin—atherosclerosis	0.000481	0.00411	CcSEcCtD
Imipramine—Erectile dysfunction—Niacin—atherosclerosis	0.000476	0.00407	CcSEcCtD
Imipramine—Hepatitis—Ezetimibe—atherosclerosis	0.000472	0.00404	CcSEcCtD
Imipramine—Erectile dysfunction—Pravastatin—atherosclerosis	0.000468	0.004	CcSEcCtD
Imipramine—Photosensitivity reaction—Pravastatin—atherosclerosis	0.000464	0.00397	CcSEcCtD
Imipramine—Weight increased—Pravastatin—atherosclerosis	0.000463	0.00396	CcSEcCtD
Imipramine—Weight decreased—Pravastatin—atherosclerosis	0.00046	0.00393	CcSEcCtD
Imipramine—KCND3—liver—atherosclerosis	0.000456	0.0197	CbGeAlD
Imipramine—Hepatitis—Simvastatin—atherosclerosis	0.00045	0.00385	CcSEcCtD
Imipramine—Stomatitis—Niacin—atherosclerosis	0.000449	0.00384	CcSEcCtD
Imipramine—Jaundice—Niacin—atherosclerosis	0.000449	0.00384	CcSEcCtD
Imipramine—Acute coronary syndrome—Pravastatin—atherosclerosis	0.000447	0.00382	CcSEcCtD
Imipramine—Flushing—Lovastatin—atherosclerosis	0.000447	0.00382	CcSEcCtD
Imipramine—Neuropathy peripheral—Pravastatin—atherosclerosis	0.000444	0.0038	CcSEcCtD
Imipramine—Myocardial infarction—Pravastatin—atherosclerosis	0.000444	0.0038	CcSEcCtD
Imipramine—HTR2A—endothelium—atherosclerosis	0.000443	0.0191	CbGeAlD
Imipramine—Jaundice—Pravastatin—atherosclerosis	0.000442	0.00378	CcSEcCtD
Imipramine—Flushing—Ezetimibe—atherosclerosis	0.000438	0.00375	CcSEcCtD
Imipramine—Angiopathy—Ezetimibe—atherosclerosis	0.000428	0.00366	CcSEcCtD
Imipramine—Immune system disorder—Ezetimibe—atherosclerosis	0.000426	0.00365	CcSEcCtD
Imipramine—Mediastinal disorder—Ezetimibe—atherosclerosis	0.000425	0.00364	CcSEcCtD
Imipramine—Alopecia—Lovastatin—atherosclerosis	0.000425	0.00364	CcSEcCtD
Imipramine—Flushing—Simvastatin—atherosclerosis	0.000418	0.00357	CcSEcCtD
Imipramine—Alopecia—Ezetimibe—atherosclerosis	0.000417	0.00357	CcSEcCtD
Imipramine—CYP2C18—liver—atherosclerosis	0.000415	0.0179	CbGeAlD
Imipramine—Mental disorder—Ezetimibe—atherosclerosis	0.000413	0.00354	CcSEcCtD
Imipramine—Hepatitis—Niacin—atherosclerosis	0.000413	0.00353	CcSEcCtD
Imipramine—Hypoaesthesia—Niacin—atherosclerosis	0.000411	0.00352	CcSEcCtD
Imipramine—Malnutrition—Ezetimibe—atherosclerosis	0.000411	0.00351	CcSEcCtD
Imipramine—Dysgeusia—Lovastatin—atherosclerosis	0.00041	0.00351	CcSEcCtD
Imipramine—HTR2A—blood vessel—atherosclerosis	0.000409	0.0176	CbGeAlD
Imipramine—Pheniramine—HRH1—atherosclerosis	0.000409	0.067	CrCbGaD
Imipramine—Hepatitis—Pravastatin—atherosclerosis	0.000407	0.00348	CcSEcCtD
Imipramine—Confusional state—Rosuvastatin—atherosclerosis	0.000407	0.00348	CcSEcCtD
Imipramine—SLC22A3—connective tissue—atherosclerosis	0.000407	0.0175	CbGeAlD
Imipramine—Hypoaesthesia—Pravastatin—atherosclerosis	0.000405	0.00346	CcSEcCtD
Imipramine—Infection—Rosuvastatin—atherosclerosis	0.000401	0.00343	CcSEcCtD
Imipramine—Methdilazine—HRH1—atherosclerosis	0.0004	0.0656	CrCbGaD
Imipramine—Alopecia—Simvastatin—atherosclerosis	0.000398	0.0034	CcSEcCtD
Imipramine—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000396	0.00338	CcSEcCtD
Imipramine—CYP3A7—liver—atherosclerosis	0.000395	0.017	CbGeAlD
Imipramine—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000395	0.00338	CcSEcCtD
Imipramine—Vision blurred—Lovastatin—atherosclerosis	0.000395	0.00338	CcSEcCtD
Imipramine—Mental disorder—Simvastatin—atherosclerosis	0.000394	0.00337	CcSEcCtD
Imipramine—Tremor—Lovastatin—atherosclerosis	0.000392	0.00336	CcSEcCtD
Imipramine—Ill-defined disorder—Lovastatin—atherosclerosis	0.000389	0.00332	CcSEcCtD
Imipramine—Eye disorder—Niacin—atherosclerosis	0.000386	0.0033	CcSEcCtD
Imipramine—Tinnitus—Niacin—atherosclerosis	0.000385	0.00329	CcSEcCtD
Imipramine—Dysgeusia—Simvastatin—atherosclerosis	0.000384	0.00328	CcSEcCtD
Imipramine—Flushing—Niacin—atherosclerosis	0.000384	0.00328	CcSEcCtD
Imipramine—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000381	0.00326	CcSEcCtD
Imipramine—Tinnitus—Pravastatin—atherosclerosis	0.000379	0.00324	CcSEcCtD
Imipramine—Malaise—Lovastatin—atherosclerosis	0.000378	0.00323	CcSEcCtD
Imipramine—Flushing—Pravastatin—atherosclerosis	0.000378	0.00323	CcSEcCtD
Imipramine—Cardiac disorder—Pravastatin—atherosclerosis	0.000378	0.00323	CcSEcCtD
Imipramine—CHRM2—cardiovascular system—atherosclerosis	0.000377	0.0163	CbGeAlD
Imipramine—Angiopathy—Niacin—atherosclerosis	0.000375	0.00321	CcSEcCtD
Imipramine—Leukopenia—Lovastatin—atherosclerosis	0.000375	0.00321	CcSEcCtD
Imipramine—Clofedanol—HRH1—atherosclerosis	0.000372	0.061	CrCbGaD
Imipramine—Malaise—Ezetimibe—atherosclerosis	0.00037	0.00317	CcSEcCtD
Imipramine—Vision blurred—Simvastatin—atherosclerosis	0.000369	0.00316	CcSEcCtD
Imipramine—Arrhythmia—Niacin—atherosclerosis	0.000369	0.00316	CcSEcCtD
Imipramine—Tremor—Simvastatin—atherosclerosis	0.000367	0.00314	CcSEcCtD
Imipramine—Alopecia—Niacin—atherosclerosis	0.000365	0.00312	CcSEcCtD
Imipramine—Insomnia—Rosuvastatin—atherosclerosis	0.000365	0.00312	CcSEcCtD
Imipramine—Ill-defined disorder—Simvastatin—atherosclerosis	0.000364	0.00311	CcSEcCtD
Imipramine—Arrhythmia—Pravastatin—atherosclerosis	0.000363	0.00311	CcSEcCtD
Imipramine—Palpitations—Ezetimibe—atherosclerosis	0.000363	0.0031	CcSEcCtD
Imipramine—Paraesthesia—Rosuvastatin—atherosclerosis	0.000362	0.0031	CcSEcCtD
Imipramine—Malnutrition—Niacin—atherosclerosis	0.00036	0.00308	CcSEcCtD
Imipramine—Alopecia—Pravastatin—atherosclerosis	0.00036	0.00307	CcSEcCtD
Imipramine—Anxiety—Lovastatin—atherosclerosis	0.000355	0.00304	CcSEcCtD
Imipramine—Dyspepsia—Rosuvastatin—atherosclerosis	0.000355	0.00304	CcSEcCtD
Imipramine—Hypertension—Ezetimibe—atherosclerosis	0.000355	0.00303	CcSEcCtD
Imipramine—Malaise—Simvastatin—atherosclerosis	0.000353	0.00302	CcSEcCtD
Imipramine—Tension—Niacin—atherosclerosis	0.000353	0.00302	CcSEcCtD
Imipramine—Discomfort—Lovastatin—atherosclerosis	0.000352	0.00301	CcSEcCtD
Imipramine—Leukopenia—Simvastatin—atherosclerosis	0.000351	0.003	CcSEcCtD
Imipramine—Nervousness—Niacin—atherosclerosis	0.000349	0.00299	CcSEcCtD
Imipramine—Dry mouth—Lovastatin—atherosclerosis	0.000349	0.00298	CcSEcCtD
Imipramine—Tension—Pravastatin—atherosclerosis	0.000348	0.00297	CcSEcCtD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000347	0.00297	CcSEcCtD
Imipramine—Dysgeusia—Pravastatin—atherosclerosis	0.000347	0.00297	CcSEcCtD
Imipramine—Discomfort—Ezetimibe—atherosclerosis	0.000346	0.00295	CcSEcCtD
Imipramine—Constipation—Rosuvastatin—atherosclerosis	0.000345	0.00295	CcSEcCtD
Imipramine—Confusional state—Lovastatin—atherosclerosis	0.000345	0.00295	CcSEcCtD
Imipramine—Nervousness—Pravastatin—atherosclerosis	0.000344	0.00294	CcSEcCtD
Imipramine—CHRM1—cardiovascular system—atherosclerosis	0.000343	0.0148	CbGeAlD
Imipramine—SLC22A4—adipose tissue—atherosclerosis	0.000343	0.0148	CbGeAlD
Imipramine—Dry mouth—Ezetimibe—atherosclerosis	0.000342	0.00292	CcSEcCtD
Imipramine—Anaphylactic shock—Lovastatin—atherosclerosis	0.000342	0.00292	CcSEcCtD
Imipramine—Doxylamine—HRH1—atherosclerosis	0.00034	0.0558	CrCbGaD
Imipramine—Infection—Lovastatin—atherosclerosis	0.00034	0.0029	CcSEcCtD
Imipramine—Vision blurred—Niacin—atherosclerosis	0.000339	0.0029	CcSEcCtD
Imipramine—Confusional state—Ezetimibe—atherosclerosis	0.000338	0.00289	CcSEcCtD
Imipramine—CYP3A7-CYP3A51P—liver—atherosclerosis	0.000336	0.0145	CbGeAlD
Imipramine—HTR7—connective tissue—atherosclerosis	0.000336	0.0145	CbGeAlD
Imipramine—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000335	0.00287	CcSEcCtD
Imipramine—Thrombocytopenia—Lovastatin—atherosclerosis	0.000335	0.00286	CcSEcCtD
Imipramine—Vision blurred—Pravastatin—atherosclerosis	0.000334	0.00285	CcSEcCtD
Imipramine—Infection—Ezetimibe—atherosclerosis	0.000333	0.00285	CcSEcCtD
Imipramine—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000332	0.00284	CcSEcCtD
Imipramine—Anxiety—Simvastatin—atherosclerosis	0.000332	0.00284	CcSEcCtD
Imipramine—Tremor—Pravastatin—atherosclerosis	0.000332	0.00284	CcSEcCtD
Imipramine—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.00033	0.00282	CcSEcCtD
Imipramine—Discomfort—Simvastatin—atherosclerosis	0.00033	0.00282	CcSEcCtD
Imipramine—Nervous system disorder—Ezetimibe—atherosclerosis	0.000329	0.00281	CcSEcCtD
Imipramine—Ill-defined disorder—Pravastatin—atherosclerosis	0.000329	0.00281	CcSEcCtD
Imipramine—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000328	0.00281	CcSEcCtD
Imipramine—SLC22A1—adipose tissue—atherosclerosis	0.000327	0.0141	CbGeAlD
Imipramine—Anorexia—Lovastatin—atherosclerosis	0.000326	0.00279	CcSEcCtD
Imipramine—Skin disorder—Ezetimibe—atherosclerosis	0.000326	0.00278	CcSEcCtD
Imipramine—Tripelennamine—HRH1—atherosclerosis	0.000324	0.0531	CrCbGaD
Imipramine—Syncope—Niacin—atherosclerosis	0.000323	0.00276	CcSEcCtD
Imipramine—Confusional state—Simvastatin—atherosclerosis	0.000322	0.00276	CcSEcCtD
Imipramine—Leukopenia—Niacin—atherosclerosis	0.000322	0.00275	CcSEcCtD
Imipramine—Urticaria—Rosuvastatin—atherosclerosis	0.00032	0.00274	CcSEcCtD
Imipramine—Olopatadine—HRH1—atherosclerosis	0.00032	0.0524	CrCbGaD
Imipramine—Anaphylactic shock—Simvastatin—atherosclerosis	0.00032	0.00273	CcSEcCtD
Imipramine—Oedema—Simvastatin—atherosclerosis	0.00032	0.00273	CcSEcCtD
Imipramine—Malaise—Pravastatin—atherosclerosis	0.000319	0.00273	CcSEcCtD
Imipramine—Abdominal pain—Rosuvastatin—atherosclerosis	0.000319	0.00273	CcSEcCtD
Imipramine—Palpitations—Niacin—atherosclerosis	0.000318	0.00272	CcSEcCtD
Imipramine—Infection—Simvastatin—atherosclerosis	0.000318	0.00272	CcSEcCtD
Imipramine—Leukopenia—Pravastatin—atherosclerosis	0.000317	0.00271	CcSEcCtD
Imipramine—Loss of consciousness—Niacin—atherosclerosis	0.000316	0.0027	CcSEcCtD
Imipramine—Thrombocytopenia—Simvastatin—atherosclerosis	0.000313	0.00268	CcSEcCtD
Imipramine—SLC22A3—adipose tissue—atherosclerosis	0.000312	0.0135	CbGeAlD
Imipramine—Insomnia—Lovastatin—atherosclerosis	0.000309	0.00264	CcSEcCtD
Imipramine—Paraesthesia—Lovastatin—atherosclerosis	0.000307	0.00262	CcSEcCtD
Imipramine—HTR1A—cardiovascular system—atherosclerosis	0.000306	0.0132	CbGeAlD
Imipramine—Hypertension—Pravastatin—atherosclerosis	0.000306	0.00261	CcSEcCtD
Imipramine—Anorexia—Simvastatin—atherosclerosis	0.000305	0.00261	CcSEcCtD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000304	0.0026	CcSEcCtD
Imipramine—Insomnia—Ezetimibe—atherosclerosis	0.000303	0.00259	CcSEcCtD
Imipramine—Paraesthesia—Ezetimibe—atherosclerosis	0.000301	0.00257	CcSEcCtD
Imipramine—Dyspepsia—Lovastatin—atherosclerosis	0.000301	0.00257	CcSEcCtD
Imipramine—Anxiety—Pravastatin—atherosclerosis	0.000301	0.00257	CcSEcCtD
Imipramine—Dry mouth—Niacin—atherosclerosis	0.0003	0.00256	CcSEcCtD
Imipramine—Discomfort—Pravastatin—atherosclerosis	0.000298	0.00255	CcSEcCtD
Imipramine—Dimetindene—HRH1—atherosclerosis	0.000297	0.0488	CrCbGaD
Imipramine—Decreased appetite—Lovastatin—atherosclerosis	0.000297	0.00254	CcSEcCtD
Imipramine—Dyspepsia—Ezetimibe—atherosclerosis	0.000295	0.00252	CcSEcCtD
Imipramine—Fatigue—Lovastatin—atherosclerosis	0.000295	0.00252	CcSEcCtD
Imipramine—Oedema—Niacin—atherosclerosis	0.000294	0.00251	CcSEcCtD
Imipramine—Anaphylactic shock—Niacin—atherosclerosis	0.000294	0.00251	CcSEcCtD
Imipramine—Constipation—Lovastatin—atherosclerosis	0.000292	0.0025	CcSEcCtD
Imipramine—HTR7—cardiovascular system—atherosclerosis	0.000292	0.0126	CbGeAlD
Imipramine—Alimemazine—HRH1—atherosclerosis	0.000292	0.0479	CrCbGaD
Imipramine—Confusional state—Pravastatin—atherosclerosis	0.000291	0.00249	CcSEcCtD
Imipramine—Decreased appetite—Ezetimibe—atherosclerosis	0.000291	0.00249	CcSEcCtD
Imipramine—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000289	0.00248	CcSEcCtD
Imipramine—Asthenia—Rosuvastatin—atherosclerosis	0.000289	0.00247	CcSEcCtD
Imipramine—Insomnia—Simvastatin—atherosclerosis	0.000289	0.00247	CcSEcCtD
Imipramine—Anaphylactic shock—Pravastatin—atherosclerosis	0.000289	0.00247	CcSEcCtD
Imipramine—Oedema—Pravastatin—atherosclerosis	0.000289	0.00247	CcSEcCtD
Imipramine—Fatigue—Ezetimibe—atherosclerosis	0.000289	0.00247	CcSEcCtD
Imipramine—Shock—Niacin—atherosclerosis	0.000289	0.00247	CcSEcCtD
Imipramine—Infection—Pravastatin—atherosclerosis	0.000287	0.00246	CcSEcCtD
Imipramine—Paraesthesia—Simvastatin—atherosclerosis	0.000287	0.00246	CcSEcCtD
Imipramine—Constipation—Ezetimibe—atherosclerosis	0.000287	0.00245	CcSEcCtD
Imipramine—Tachycardia—Niacin—atherosclerosis	0.000287	0.00245	CcSEcCtD
Imipramine—Pruritus—Rosuvastatin—atherosclerosis	0.000285	0.00244	CcSEcCtD
Imipramine—Skin disorder—Niacin—atherosclerosis	0.000285	0.00244	CcSEcCtD
Imipramine—Hyperhidrosis—Niacin—atherosclerosis	0.000284	0.00243	CcSEcCtD
Imipramine—Thrombocytopenia—Pravastatin—atherosclerosis	0.000283	0.00242	CcSEcCtD
Imipramine—ADRA1A—cardiovascular system—atherosclerosis	0.000282	0.0122	CbGeAlD
Imipramine—Feeling abnormal—Lovastatin—atherosclerosis	0.000282	0.00241	CcSEcCtD
Imipramine—Dyspepsia—Simvastatin—atherosclerosis	0.000281	0.00241	CcSEcCtD
Imipramine—Anorexia—Niacin—atherosclerosis	0.00028	0.00239	CcSEcCtD
Imipramine—Gastrointestinal pain—Lovastatin—atherosclerosis	0.00028	0.00239	CcSEcCtD
Imipramine—Hyperhidrosis—Pravastatin—atherosclerosis	0.000279	0.00239	CcSEcCtD
Imipramine—Decreased appetite—Simvastatin—atherosclerosis	0.000278	0.00238	CcSEcCtD
Imipramine—Feeling abnormal—Ezetimibe—atherosclerosis	0.000276	0.00236	CcSEcCtD
Imipramine—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000276	0.00236	CcSEcCtD
Imipramine—Diarrhoea—Rosuvastatin—atherosclerosis	0.000276	0.00236	CcSEcCtD
Imipramine—Fatigue—Simvastatin—atherosclerosis	0.000276	0.00236	CcSEcCtD
Imipramine—Anorexia—Pravastatin—atherosclerosis	0.000276	0.00236	CcSEcCtD
Imipramine—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000274	0.00234	CcSEcCtD
Imipramine—Constipation—Simvastatin—atherosclerosis	0.000273	0.00234	CcSEcCtD
Imipramine—KCNH2—cardiovascular system—atherosclerosis	0.000272	0.0117	CbGeAlD
Imipramine—Urticaria—Lovastatin—atherosclerosis	0.000272	0.00232	CcSEcCtD
Imipramine—CHRM3—adipose tissue—atherosclerosis	0.000271	0.0117	CbGeAlD
Imipramine—Abdominal pain—Lovastatin—atherosclerosis	0.00027	0.00231	CcSEcCtD
Imipramine—Body temperature increased—Lovastatin—atherosclerosis	0.00027	0.00231	CcSEcCtD
Imipramine—ABCB1—blood vessel—atherosclerosis	0.000268	0.0116	CbGeAlD
Imipramine—Epinastine—HRH1—atherosclerosis	0.000267	0.0438	CrCbGaD
Imipramine—Dizziness—Rosuvastatin—atherosclerosis	0.000267	0.00228	CcSEcCtD
Imipramine—Urticaria—Ezetimibe—atherosclerosis	0.000266	0.00228	CcSEcCtD
Imipramine—Bromodiphenhydramine—HRH1—atherosclerosis	0.000266	0.0436	CrCbGaD
Imipramine—Insomnia—Niacin—atherosclerosis	0.000266	0.00227	CcSEcCtD
Imipramine—Body temperature increased—Ezetimibe—atherosclerosis	0.000265	0.00227	CcSEcCtD
Imipramine—Abdominal pain—Ezetimibe—atherosclerosis	0.000265	0.00227	CcSEcCtD
Imipramine—Paraesthesia—Niacin—atherosclerosis	0.000264	0.00225	CcSEcCtD
Imipramine—Feeling abnormal—Simvastatin—atherosclerosis	0.000263	0.00225	CcSEcCtD
Imipramine—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000261	0.00224	CcSEcCtD
Imipramine—Insomnia—Pravastatin—atherosclerosis	0.000261	0.00224	CcSEcCtD
Imipramine—Somnolence—Niacin—atherosclerosis	0.000261	0.00223	CcSEcCtD
Imipramine—Paraesthesia—Pravastatin—atherosclerosis	0.00026	0.00222	CcSEcCtD
Imipramine—Dyspepsia—Niacin—atherosclerosis	0.000258	0.00221	CcSEcCtD
Imipramine—Decreased appetite—Niacin—atherosclerosis	0.000255	0.00218	CcSEcCtD
Imipramine—Dyspepsia—Pravastatin—atherosclerosis	0.000254	0.00218	CcSEcCtD
Imipramine—Rash—Rosuvastatin—atherosclerosis	0.000254	0.00217	CcSEcCtD
Imipramine—Dermatitis—Rosuvastatin—atherosclerosis	0.000254	0.00217	CcSEcCtD
Imipramine—Urticaria—Simvastatin—atherosclerosis	0.000254	0.00217	CcSEcCtD
Imipramine—Gastrointestinal disorder—Niacin—atherosclerosis	0.000253	0.00217	CcSEcCtD
Imipramine—Abdominal pain—Simvastatin—atherosclerosis	0.000253	0.00216	CcSEcCtD
Imipramine—Body temperature increased—Simvastatin—atherosclerosis	0.000253	0.00216	CcSEcCtD
Imipramine—Headache—Rosuvastatin—atherosclerosis	0.000253	0.00216	CcSEcCtD
Imipramine—Mequitazine—HRH1—atherosclerosis	0.000251	0.0412	CrCbGaD
Imipramine—Decreased appetite—Pravastatin—atherosclerosis	0.000251	0.00215	CcSEcCtD
Imipramine—HRH1—connective tissue—atherosclerosis	0.000251	0.0108	CbGeAlD
Imipramine—ORM1—liver—atherosclerosis	0.00025	0.0108	CbGeAlD
Imipramine—Fatigue—Pravastatin—atherosclerosis	0.000249	0.00213	CcSEcCtD
Imipramine—ADRA1A—adipose tissue—atherosclerosis	0.000249	0.0107	CbGeAlD
Imipramine—Constipation—Pravastatin—atherosclerosis	0.000247	0.00211	CcSEcCtD
Imipramine—Asthenia—Lovastatin—atherosclerosis	0.000245	0.0021	CcSEcCtD
Imipramine—Pruritus—Lovastatin—atherosclerosis	0.000242	0.00207	CcSEcCtD
Imipramine—Asthenia—Ezetimibe—atherosclerosis	0.000241	0.00206	CcSEcCtD
Imipramine—Gastrointestinal pain—Niacin—atherosclerosis	0.00024	0.00205	CcSEcCtD
Imipramine—Nausea—Rosuvastatin—atherosclerosis	0.00024	0.00205	CcSEcCtD
Imipramine—Feeling abnormal—Pravastatin—atherosclerosis	0.000238	0.00204	CcSEcCtD
Imipramine—Pruritus—Ezetimibe—atherosclerosis	0.000237	0.00203	CcSEcCtD
Imipramine—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000236	0.00202	CcSEcCtD
Imipramine—Diarrhoea—Lovastatin—atherosclerosis	0.000234	0.002	CcSEcCtD
Imipramine—Urticaria—Niacin—atherosclerosis	0.000233	0.00199	CcSEcCtD
Imipramine—Abdominal pain—Niacin—atherosclerosis	0.000232	0.00198	CcSEcCtD
Imipramine—Body temperature increased—Niacin—atherosclerosis	0.000232	0.00198	CcSEcCtD
Imipramine—Maprotiline—HRH1—atherosclerosis	0.00023	0.0377	CrCbGaD
Imipramine—Urticaria—Pravastatin—atherosclerosis	0.00023	0.00196	CcSEcCtD
Imipramine—Asthenia—Simvastatin—atherosclerosis	0.000229	0.00196	CcSEcCtD
Imipramine—Diarrhoea—Ezetimibe—atherosclerosis	0.000229	0.00196	CcSEcCtD
Imipramine—SLC22A1—liver—atherosclerosis	0.000229	0.00988	CbGeAlD
Imipramine—Body temperature increased—Pravastatin—atherosclerosis	0.000229	0.00195	CcSEcCtD
Imipramine—Abdominal pain—Pravastatin—atherosclerosis	0.000229	0.00195	CcSEcCtD
Imipramine—Pruritus—Simvastatin—atherosclerosis	0.000226	0.00193	CcSEcCtD
Imipramine—Dizziness—Lovastatin—atherosclerosis	0.000226	0.00193	CcSEcCtD
Imipramine—Benazepril—MTHFR—atherosclerosis	0.000224	0.0367	CrCbGaD
Imipramine—CYP2B6—cardiovascular system—atherosclerosis	0.000223	0.00964	CbGeAlD
Imipramine—Dizziness—Ezetimibe—atherosclerosis	0.000222	0.0019	CcSEcCtD
Imipramine—SLC22A3—liver—atherosclerosis	0.000219	0.00944	CbGeAlD
Imipramine—Diarrhoea—Simvastatin—atherosclerosis	0.000219	0.00187	CcSEcCtD
Imipramine—Vomiting—Lovastatin—atherosclerosis	0.000217	0.00186	CcSEcCtD
Imipramine—Rash—Lovastatin—atherosclerosis	0.000216	0.00184	CcSEcCtD
Imipramine—Dermatitis—Lovastatin—atherosclerosis	0.000215	0.00184	CcSEcCtD
Imipramine—Headache—Lovastatin—atherosclerosis	0.000214	0.00183	CcSEcCtD
Imipramine—Vomiting—Ezetimibe—atherosclerosis	0.000213	0.00182	CcSEcCtD
Imipramine—Dizziness—Simvastatin—atherosclerosis	0.000211	0.00181	CcSEcCtD
Imipramine—Rash—Ezetimibe—atherosclerosis	0.000211	0.00181	CcSEcCtD
Imipramine—Dermatitis—Ezetimibe—atherosclerosis	0.000211	0.00181	CcSEcCtD
Imipramine—Asthenia—Niacin—atherosclerosis	0.000211	0.0018	CcSEcCtD
Imipramine—Headache—Ezetimibe—atherosclerosis	0.00021	0.0018	CcSEcCtD
Imipramine—CYP2E1—cardiovascular system—atherosclerosis	0.00021	0.00905	CbGeAlD
Imipramine—HTR2A—connective tissue—atherosclerosis	0.000209	0.00904	CbGeAlD
Imipramine—Pruritus—Niacin—atherosclerosis	0.000208	0.00178	CcSEcCtD
Imipramine—Asthenia—Pravastatin—atherosclerosis	0.000207	0.00177	CcSEcCtD
Imipramine—Pruritus—Pravastatin—atherosclerosis	0.000205	0.00175	CcSEcCtD
Imipramine—Vomiting—Simvastatin—atherosclerosis	0.000203	0.00174	CcSEcCtD
Imipramine—Nausea—Lovastatin—atherosclerosis	0.000203	0.00174	CcSEcCtD
Imipramine—Rash—Simvastatin—atherosclerosis	0.000202	0.00172	CcSEcCtD
Imipramine—Dermatitis—Simvastatin—atherosclerosis	0.000201	0.00172	CcSEcCtD
Imipramine—Diarrhoea—Niacin—atherosclerosis	0.000201	0.00172	CcSEcCtD
Imipramine—Headache—Simvastatin—atherosclerosis	0.0002	0.00171	CcSEcCtD
Imipramine—Nausea—Ezetimibe—atherosclerosis	0.000199	0.0017	CcSEcCtD
Imipramine—Diarrhoea—Pravastatin—atherosclerosis	0.000198	0.00169	CcSEcCtD
Imipramine—Dizziness—Niacin—atherosclerosis	0.000194	0.00166	CcSEcCtD
Imipramine—HRH1—adipose tissue—atherosclerosis	0.000192	0.0083	CbGeAlD
Imipramine—Dizziness—Pravastatin—atherosclerosis	0.000191	0.00163	CcSEcCtD
Imipramine—Nausea—Simvastatin—atherosclerosis	0.00019	0.00162	CcSEcCtD
Imipramine—Vomiting—Niacin—atherosclerosis	0.000187	0.0016	CcSEcCtD
Imipramine—Rash—Niacin—atherosclerosis	0.000185	0.00158	CcSEcCtD
Imipramine—Dermatitis—Niacin—atherosclerosis	0.000185	0.00158	CcSEcCtD
Imipramine—Headache—Niacin—atherosclerosis	0.000184	0.00157	CcSEcCtD
Imipramine—Vomiting—Pravastatin—atherosclerosis	0.000184	0.00157	CcSEcCtD
Imipramine—Benazepril—ACE—atherosclerosis	0.000182	0.0299	CrCbGaD
Imipramine—Rash—Pravastatin—atherosclerosis	0.000182	0.00156	CcSEcCtD
Imipramine—HTR2A—cardiovascular system—atherosclerosis	0.000182	0.00786	CbGeAlD
Imipramine—Dermatitis—Pravastatin—atherosclerosis	0.000182	0.00156	CcSEcCtD
Imipramine—Headache—Pravastatin—atherosclerosis	0.000181	0.00155	CcSEcCtD
Imipramine—HTR7—liver—atherosclerosis	0.000181	0.0078	CbGeAlD
Imipramine—CYP2C19—liver—atherosclerosis	0.000177	0.00761	CbGeAlD
Imipramine—Nausea—Niacin—atherosclerosis	0.000174	0.00149	CcSEcCtD
Imipramine—ADRA1A—liver—atherosclerosis	0.000174	0.00752	CbGeAlD
Imipramine—Nausea—Pravastatin—atherosclerosis	0.000172	0.00147	CcSEcCtD
Imipramine—Prochlorperazine—HRH1—atherosclerosis	0.000171	0.028	CrCbGaD
Imipramine—Mianserin—HRH1—atherosclerosis	0.000155	0.0253	CrCbGaD
Imipramine—CYP1A2—liver—atherosclerosis	0.000144	0.00622	CbGeAlD
Imipramine—CYP2B6—liver—atherosclerosis	0.000138	0.00596	CbGeAlD
Imipramine—Nortriptyline—HRH1—atherosclerosis	0.000138	0.0226	CrCbGaD
Imipramine—Trimipramine—HRH1—atherosclerosis	0.00013	0.0213	CrCbGaD
Imipramine—CYP2E1—liver—atherosclerosis	0.00013	0.00559	CbGeAlD
Imipramine—Diphenhydramine—HRH1—atherosclerosis	0.000128	0.0209	CrCbGaD
Imipramine—Methotrimeprazine—HRH1—atherosclerosis	0.000127	0.0208	CrCbGaD
Imipramine—Promethazine—HRH1—atherosclerosis	0.000125	0.0205	CrCbGaD
Imipramine—Doxepin—HRH1—atherosclerosis	0.000124	0.0203	CrCbGaD
Imipramine—Orphenadrine—HRH1—atherosclerosis	0.000121	0.0198	CrCbGaD
Imipramine—ABCB1—cardiovascular system—atherosclerosis	0.000119	0.00515	CbGeAlD
Imipramine—Desipramine—HRH1—atherosclerosis	0.000114	0.0186	CrCbGaD
Imipramine—HTR2A—liver—atherosclerosis	0.000113	0.00486	CbGeAlD
Imipramine—Promazine—HRH1—atherosclerosis	0.00011	0.0181	CrCbGaD
Imipramine—ABCB1—adipose tissue—atherosclerosis	0.000105	0.00454	CbGeAlD
Imipramine—CYP3A4—liver—atherosclerosis	0.000104	0.0045	CbGeAlD
Imipramine—CYP2D6—liver—atherosclerosis	0.000103	0.00443	CbGeAlD
Imipramine—Chlorpromazine—HRH1—atherosclerosis	9.69e-05	0.0159	CrCbGaD
Imipramine—Amitriptyline—HRH1—atherosclerosis	9.58e-05	0.0157	CrCbGaD
Imipramine—ABCB1—liver—atherosclerosis	7.39e-05	0.00319	CbGeAlD
Imipramine—Oxcarbazepine—ALB—atherosclerosis	5.68e-05	0.00931	CrCbGaD
Imipramine—Acepromazine—ALB—atherosclerosis	4.29e-05	0.00704	CrCbGaD
Imipramine—Thioproperazine—ALB—atherosclerosis	4.2e-05	0.00688	CrCbGaD
Imipramine—Pipotiazine—ALB—atherosclerosis	4.13e-05	0.00677	CrCbGaD
Imipramine—Clomipramine—ALB—atherosclerosis	3.26e-05	0.00535	CrCbGaD
Imipramine—Nortriptyline—ALB—atherosclerosis	3.19e-05	0.00523	CrCbGaD
Imipramine—Chlorpromazine—ALB—atherosclerosis	2.24e-05	0.00367	CrCbGaD
Imipramine—Amitriptyline—ALB—atherosclerosis	2.21e-05	0.00363	CrCbGaD
Imipramine—CYP2E1—Metabolism—ALB—atherosclerosis	2.79e-06	2.85e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—SERPINE1—atherosclerosis	2.79e-06	2.84e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—SERPINE1—atherosclerosis	2.78e-06	2.83e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—MAPK8—atherosclerosis	2.77e-06	2.82e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—TGFB1—atherosclerosis	2.77e-06	2.82e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling by GPCR—AKT1—atherosclerosis	2.76e-06	2.82e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—TGFB1—atherosclerosis	2.76e-06	2.81e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—APOE—atherosclerosis	2.75e-06	2.8e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—SERPINE1—atherosclerosis	2.75e-06	2.8e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—CXCL8—atherosclerosis	2.75e-06	2.8e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—SERPINE1—atherosclerosis	2.74e-06	2.79e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—AGT—atherosclerosis	2.74e-06	2.79e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—CXCL8—atherosclerosis	2.73e-06	2.78e-05	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—NOS3—atherosclerosis	2.73e-06	2.78e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—CAV1—atherosclerosis	2.73e-06	2.78e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—VEGFA—atherosclerosis	2.72e-06	2.77e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—APOA1—atherosclerosis	2.72e-06	2.77e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—MTHFR—atherosclerosis	2.72e-06	2.77e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—NOS3—atherosclerosis	2.72e-06	2.77e-05	CbGpPWpGaD
Imipramine—SLC22A3—Metabolism—AKT1—atherosclerosis	2.7e-06	2.75e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—STAT3—atherosclerosis	2.7e-06	2.75e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—MAPK3—atherosclerosis	2.69e-06	2.74e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—APOE—atherosclerosis	2.69e-06	2.74e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—APOB—atherosclerosis	2.68e-06	2.73e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—NOS3—atherosclerosis	2.67e-06	2.73e-05	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—NOS3—atherosclerosis	2.67e-06	2.72e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—NOS3—atherosclerosis	2.67e-06	2.72e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PPARA—atherosclerosis	2.67e-06	2.72e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—CAV1—atherosclerosis	2.66e-06	2.71e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—NOS3—atherosclerosis	2.66e-06	2.71e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—APOA1—atherosclerosis	2.66e-06	2.71e-05	CbGpPWpGaD
Imipramine—HTR1A—GPCR downstream signaling—AKT1—atherosclerosis	2.65e-06	2.7e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—NOS3—atherosclerosis	2.65e-06	2.7e-05	CbGpPWpGaD
Imipramine—HTR2C—GPCR downstream signaling—AKT1—atherosclerosis	2.64e-06	2.69e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—NOS3—atherosclerosis	2.63e-06	2.68e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—NOS3—atherosclerosis	2.62e-06	2.67e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—CXCL8—atherosclerosis	2.62e-06	2.66e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling by GPCR—IL6—atherosclerosis	2.61e-06	2.66e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—TGFB1—atherosclerosis	2.61e-06	2.66e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—GSTM1—atherosclerosis	2.61e-06	2.66e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling by GPCR—IL6—atherosclerosis	2.6e-06	2.65e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—AGT—atherosclerosis	2.58e-06	2.63e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—MAPK3—atherosclerosis	2.58e-06	2.62e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—VEGFA—atherosclerosis	2.56e-06	2.61e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—LPL—atherosclerosis	2.56e-06	2.61e-05	CbGpPWpGaD
Imipramine—CYP2C18—Metabolism—AKT1—atherosclerosis	2.55e-06	2.6e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—STAT3—atherosclerosis	2.53e-06	2.58e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—APOE—atherosclerosis	2.53e-06	2.58e-05	CbGpPWpGaD
Imipramine—ADRA1B—GPCR downstream signaling—AKT1—atherosclerosis	2.53e-06	2.57e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—ABCA1—atherosclerosis	2.52e-06	2.56e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—CAV1—atherosclerosis	2.51e-06	2.56e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—APOA1—atherosclerosis	2.5e-06	2.55e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—TGFB1—atherosclerosis	2.5e-06	2.55e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—GPX1—atherosclerosis	2.5e-06	2.54e-05	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—PTGS2—atherosclerosis	2.5e-06	2.54e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling by GPCR—IL6—atherosclerosis	2.49e-06	2.53e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—MMP9—atherosclerosis	2.48e-06	2.53e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PIK3CG—atherosclerosis	2.48e-06	2.53e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—MMP9—atherosclerosis	2.47e-06	2.52e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—NFKB1—atherosclerosis	2.46e-06	2.5e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—NFKB1—atherosclerosis	2.45e-06	2.49e-05	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—PTGS2—atherosclerosis	2.44e-06	2.49e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—CD36—atherosclerosis	2.43e-06	2.48e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PIK3CG—atherosclerosis	2.42e-06	2.47e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—MAPK3—atherosclerosis	2.42e-06	2.47e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—MAPK8—atherosclerosis	2.42e-06	2.46e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—CXCL8—atherosclerosis	2.41e-06	2.46e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling by GPCR—AKT1—atherosclerosis	2.41e-06	2.45e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—MAPK8—atherosclerosis	2.4e-06	2.45e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PPARG—atherosclerosis	2.4e-06	2.44e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling by GPCR—AKT1—atherosclerosis	2.4e-06	2.44e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—CXCL8—atherosclerosis	2.37e-06	2.42e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—CXCL8—atherosclerosis	2.37e-06	2.41e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—MMP9—atherosclerosis	2.37e-06	2.41e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—CXCL8—atherosclerosis	2.36e-06	2.4e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—CXCL8—atherosclerosis	2.35e-06	2.4e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—INS—atherosclerosis	2.35e-06	2.4e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—TGFB1—atherosclerosis	2.35e-06	2.39e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—NFKB1—atherosclerosis	2.34e-06	2.38e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PPARG—atherosclerosis	2.34e-06	2.38e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—CXCL8—atherosclerosis	2.33e-06	2.37e-05	CbGpPWpGaD
Imipramine—DRD2—GPCR downstream signaling—AKT1—atherosclerosis	2.33e-06	2.37e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—CXCL8—atherosclerosis	2.32e-06	2.37e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—MTHFR—atherosclerosis	2.3e-06	2.35e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—MAPK8—atherosclerosis	2.3e-06	2.34e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—INS—atherosclerosis	2.29e-06	2.34e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling by GPCR—AKT1—atherosclerosis	2.29e-06	2.34e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—IL6—atherosclerosis	2.29e-06	2.34e-05	CbGpPWpGaD
Imipramine—HTR2A—GPCR downstream signaling—AKT1—atherosclerosis	2.29e-06	2.34e-05	CbGpPWpGaD
Imipramine—HRH1—GPCR downstream signaling—AKT1—atherosclerosis	2.29e-06	2.33e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PIK3CG—atherosclerosis	2.28e-06	2.33e-05	CbGpPWpGaD
Imipramine—CHRM1—GPCR downstream signaling—AKT1—atherosclerosis	2.28e-06	2.32e-05	CbGpPWpGaD
Imipramine—CHRM3—GPCR downstream signaling—AKT1—atherosclerosis	2.27e-06	2.32e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PPARA—atherosclerosis	2.26e-06	2.3e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—IL6—atherosclerosis	2.26e-06	2.3e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—IL6—atherosclerosis	2.25e-06	2.29e-05	CbGpPWpGaD
Imipramine—CHRM2—GPCR downstream signaling—AKT1—atherosclerosis	2.25e-06	2.29e-05	CbGpPWpGaD
Imipramine—ADRA1A—GPCR downstream signaling—AKT1—atherosclerosis	2.24e-06	2.29e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—IL6—atherosclerosis	2.24e-06	2.29e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—IL6—atherosclerosis	2.24e-06	2.28e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—VEGFA—atherosclerosis	2.23e-06	2.27e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—VEGFA—atherosclerosis	2.22e-06	2.26e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—IL6—atherosclerosis	2.22e-06	2.26e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—IL6—atherosclerosis	2.21e-06	2.25e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—STAT3—atherosclerosis	2.21e-06	2.25e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PPARG—atherosclerosis	2.2e-06	2.25e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—STAT3—atherosclerosis	2.2e-06	2.24e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—AGT—atherosclerosis	2.19e-06	2.23e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—MMP9—atherosclerosis	2.18e-06	2.22e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—INS—atherosclerosis	2.16e-06	2.2e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—HMOX1—atherosclerosis	2.16e-06	2.2e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—NFKB1—atherosclerosis	2.16e-06	2.2e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—ALB—atherosclerosis	2.16e-06	2.2e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—MMP9—atherosclerosis	2.15e-06	2.19e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—APOE—atherosclerosis	2.14e-06	2.18e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—MMP9—atherosclerosis	2.14e-06	2.18e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—MMP9—atherosclerosis	2.13e-06	2.17e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—MMP9—atherosclerosis	2.13e-06	2.17e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—CAV1—atherosclerosis	2.12e-06	2.16e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—VEGFA—atherosclerosis	2.12e-06	2.16e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—NFKB1—atherosclerosis	2.12e-06	2.16e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—MAPK8—atherosclerosis	2.12e-06	2.16e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—APOA1—atherosclerosis	2.12e-06	2.16e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—NFKB1—atherosclerosis	2.12e-06	2.16e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—AKT1—atherosclerosis	2.12e-06	2.16e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—NFKB1—atherosclerosis	2.11e-06	2.15e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—MAPK3—atherosclerosis	2.11e-06	2.15e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—MMP9—atherosclerosis	2.11e-06	2.15e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—NFKB1—atherosclerosis	2.11e-06	2.14e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—ALB—atherosclerosis	2.1e-06	2.14e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—STAT3—atherosclerosis	2.1e-06	2.14e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—MMP9—atherosclerosis	2.1e-06	2.14e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—MAPK3—atherosclerosis	2.1e-06	2.14e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—MAPK8—atherosclerosis	2.09e-06	2.13e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—NFKB1—atherosclerosis	2.08e-06	2.12e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—IL6—atherosclerosis	2.08e-06	2.12e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—MAPK8—atherosclerosis	2.08e-06	2.12e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—IL6—atherosclerosis	2.08e-06	2.12e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—AKT1—atherosclerosis	2.08e-06	2.12e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—NFKB1—atherosclerosis	2.08e-06	2.12e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—AKT1—atherosclerosis	2.08e-06	2.12e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—MAPK8—atherosclerosis	2.08e-06	2.12e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—AKT1—atherosclerosis	2.07e-06	2.11e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—MAPK8—atherosclerosis	2.07e-06	2.11e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—APOB—atherosclerosis	2.07e-06	2.11e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—AKT1—atherosclerosis	2.06e-06	2.1e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—NOS3—atherosclerosis	2.06e-06	2.1e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—MAPK8—atherosclerosis	2.05e-06	2.09e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—TGFB1—atherosclerosis	2.05e-06	2.09e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—AKT1—atherosclerosis	2.04e-06	2.08e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—MAPK8—atherosclerosis	2.04e-06	2.08e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—AKT1—atherosclerosis	2.04e-06	2.08e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—TGFB1—atherosclerosis	2.04e-06	2.08e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—NOS3—atherosclerosis	2.01e-06	2.05e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—GSTM1—atherosclerosis	2.01e-06	2.05e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—MAPK3—atherosclerosis	2.01e-06	2.05e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—ALB—atherosclerosis	1.98e-06	2.02e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—LPL—atherosclerosis	1.97e-06	2.01e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—IL6—atherosclerosis	1.97e-06	2e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—VEGFA—atherosclerosis	1.96e-06	2e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—TGFB1—atherosclerosis	1.95e-06	1.99e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—STAT3—atherosclerosis	1.94e-06	1.98e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PIK3CG—atherosclerosis	1.94e-06	1.97e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—VEGFA—atherosclerosis	1.93e-06	1.96e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—GPX1—atherosclerosis	1.93e-06	1.96e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—VEGFA—atherosclerosis	1.92e-06	1.96e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—AKT1—atherosclerosis	1.92e-06	1.96e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—AKT1—atherosclerosis	1.92e-06	1.96e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—VEGFA—atherosclerosis	1.92e-06	1.95e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—VEGFA—atherosclerosis	1.91e-06	1.95e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—STAT3—atherosclerosis	1.91e-06	1.94e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—STAT3—atherosclerosis	1.9e-06	1.94e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—STAT3—atherosclerosis	1.9e-06	1.93e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—NOS3—atherosclerosis	1.9e-06	1.93e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—VEGFA—atherosclerosis	1.89e-06	1.93e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—STAT3—atherosclerosis	1.89e-06	1.93e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—VEGFA—atherosclerosis	1.89e-06	1.92e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PTGS2—atherosclerosis	1.89e-06	1.92e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—IL6—atherosclerosis	1.88e-06	1.92e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—CD36—atherosclerosis	1.88e-06	1.91e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—STAT3—atherosclerosis	1.87e-06	1.91e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—STAT3—atherosclerosis	1.87e-06	1.9e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PPARG—atherosclerosis	1.87e-06	1.9e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—MAPK3—atherosclerosis	1.85e-06	1.89e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PTGS2—atherosclerosis	1.84e-06	1.88e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—INS—atherosclerosis	1.83e-06	1.87e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—MAPK3—atherosclerosis	1.82e-06	1.86e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—MAPK3—atherosclerosis	1.82e-06	1.85e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—AKT1—atherosclerosis	1.81e-06	1.85e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—MAPK3—atherosclerosis	1.81e-06	1.85e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—MAPK3—atherosclerosis	1.81e-06	1.84e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—TGFB1—atherosclerosis	1.8e-06	1.83e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—MAPK3—atherosclerosis	1.79e-06	1.82e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—MAPK3—atherosclerosis	1.78e-06	1.82e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—MTHFR—atherosclerosis	1.78e-06	1.81e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—IL6—atherosclerosis	1.77e-06	1.8e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—TGFB1—atherosclerosis	1.77e-06	1.8e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—TGFB1—atherosclerosis	1.76e-06	1.8e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—TGFB1—atherosclerosis	1.76e-06	1.79e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—TGFB1—atherosclerosis	1.75e-06	1.79e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PPARA—atherosclerosis	1.74e-06	1.78e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—AKT1—atherosclerosis	1.74e-06	1.77e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—TGFB1—atherosclerosis	1.74e-06	1.77e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PTGS2—atherosclerosis	1.73e-06	1.77e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—TGFB1—atherosclerosis	1.73e-06	1.76e-05	CbGpPWpGaD
Imipramine—CYP3A7—Metabolism—AKT1—atherosclerosis	1.7e-06	1.73e-05	CbGpPWpGaD
Imipramine—SLC22A2—Metabolism—AKT1—atherosclerosis	1.69e-06	1.73e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—AGT—atherosclerosis	1.69e-06	1.72e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—ALB—atherosclerosis	1.68e-06	1.71e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—APOE—atherosclerosis	1.66e-06	1.69e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—CAV1—atherosclerosis	1.64e-06	1.67e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—APOA1—atherosclerosis	1.64e-06	1.67e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—AKT1—atherosclerosis	1.63e-06	1.66e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—NOS3—atherosclerosis	1.61e-06	1.64e-05	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—AKT1—atherosclerosis	1.58e-06	1.61e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—IL6—atherosclerosis	1.54e-06	1.57e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—IL6—atherosclerosis	1.53e-06	1.56e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PIK3CG—atherosclerosis	1.49e-06	1.52e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PTGS2—atherosclerosis	1.47e-06	1.5e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—IL6—atherosclerosis	1.47e-06	1.5e-05	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—AKT1—atherosclerosis	1.46e-06	1.49e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PPARG—atherosclerosis	1.44e-06	1.47e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—AKT1—atherosclerosis	1.42e-06	1.45e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—AKT1—atherosclerosis	1.42e-06	1.44e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—INS—atherosclerosis	1.41e-06	1.44e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—AKT1—atherosclerosis	1.36e-06	1.38e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—IL6—atherosclerosis	1.35e-06	1.38e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—IL6—atherosclerosis	1.33e-06	1.36e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—IL6—atherosclerosis	1.33e-06	1.35e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—IL6—atherosclerosis	1.33e-06	1.35e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—IL6—atherosclerosis	1.32e-06	1.35e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—IL6—atherosclerosis	1.31e-06	1.33e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—IL6—atherosclerosis	1.31e-06	1.33e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—ALB—atherosclerosis	1.3e-06	1.32e-05	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—AKT1—atherosclerosis	1.25e-06	1.28e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—AKT1—atherosclerosis	1.25e-06	1.27e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—NOS3—atherosclerosis	1.24e-06	1.26e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—AKT1—atherosclerosis	1.23e-06	1.25e-05	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—AKT1—atherosclerosis	1.23e-06	1.25e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—AKT1—atherosclerosis	1.23e-06	1.25e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—AKT1—atherosclerosis	1.22e-06	1.25e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—AKT1—atherosclerosis	1.22e-06	1.24e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—AKT1—atherosclerosis	1.21e-06	1.23e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—AKT1—atherosclerosis	1.2e-06	1.23e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PTGS2—atherosclerosis	1.13e-06	1.16e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—AKT1—atherosclerosis	9.48e-07	9.66e-06	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—AKT1—atherosclerosis	9.25e-07	9.43e-06	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—AKT1—atherosclerosis	8.72e-07	8.88e-06	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—AKT1—atherosclerosis	7.39e-07	7.52e-06	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—AKT1—atherosclerosis	5.7e-07	5.81e-06	CbGpPWpGaD
